Aidea Pharma(SH:688488) Xin Lang Cai Jing·2026-02-13 02:08Company Overview - Eddie Pharmaceutical Co., Ltd. is located in Yangzhou, Jiangsu Province, and was established on December 15, 2009. The company went public on July 20, 2020. Its main business involves the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The revenue composition of the company includes: human-derived proteins 41.11%, new drugs 35.69%, diagnostic equipment, reagents, and others 13.62%, generic drugs 9.47%, and other supplementary products 0.11% [1] Stock Performance - On February 13, Eddie Pharmaceutical's stock rose by 5.67%, reaching a price of 17.71 yuan per share, with a trading volume of 42.1543 million yuan and a turnover rate of 0.58%. The total market capitalization is 7.452 billion yuan [1] Shareholder Information - Among the top ten circulating shareholders of Eddie Pharmaceutical, one fund under Penghua Fund ranks as a significant shareholder. Penghua Medical Technology Stock A (001230) reduced its holdings by 2.68 million shares in the third quarter, now holding 4.1255 million shares, which accounts for 0.98% of the circulating shares [2] - As of the latest data, Penghua Medical Technology Stock A has a total asset size of 1.721 billion yuan, with a year-to-date return of 3.02%, ranking 3882 out of 5569 in its category. Over the past year, it achieved a return of 70.19%, ranking 227 out of 4295 [2] Fund Management - The fund manager of Penghua Medical Technology Stock A is Jin Xiaofei, who has been in the position for 9 years and 237 days. The total asset size of the fund is 5.331 billion yuan, with the best fund return during his tenure being 243.33% and the worst being -0.92% [3]